Medizone Intl. (fka MZEIQ)

[Tane61]

MZEI: SEC - Medizone - Proxy Material

DIVISION OF CORPORATION FINANCE INFORMAL PROCEDURES REGARDING SHAREHOLDER PROPOSALS

The Division of Corporation Finance believes that its responsibility with respect to matters arising under Rule 14a-8 [17 CFR 240.14a-8], as with other matters under the proxy rules, is to aid those who must comply with the rule by offering informal advice and suggestions and to determine, initially, whether or not it may be appropriate in a particular matter to recommend enforcement action to the Commission. In connection with a shareholder proposal under Rule 14a-8, the Division’ s staff considers the information furnished to it by the company in support of its intention to exclude the proposal from the company’s proxy materials, as well as any information furnished by the proponent or the proponent’s representative.

Although Rule 14a-8(k) does not require any communications from shareholders to the Commission ’s staff, the staff will always consider information concerning alleged violations of the statutes and rules administered by the Commission, including argument s as to whether or not activities proposed to be taken would violate the statute or rule involved. The receipt by the staff of such information, however, should not be construed as changing the staff ’s informal procedures and proxy review into a formal or adversarial procedure.

It is important to note that the staff ’s no-action responses to Rule 14a-8(j) submissions reflect only informal views. The determinations reached in these no -action letters do not and cannot adjudicate the merits of a company’s position with respect to the proposal. Only a court such as a U.S. District Court can decide whether a company is obligated to include shareholder proposals in its proxy materials. Accordingly, a discretionary determination not to recommend or take Commission enforcement action does not preclude a proponent, or any shareholder of a company, from pursuing any rights he or she may have against the company in court, should the company’s management omit the proposal from the company’s proxy materials.

https://www.sec.gov/divisions/corpfin/cf-noaction/14a-8/2016/petergaide080916-14a8.pdf

Proposal for MZEI shareholders meeting scheduled for 15th December 2016

Proposed Item of Business

To amend our Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock, par value $.001 per share, available for issuance by the company, from 395 million to 450 million shares.

Supporting Statement

It has been 7 years since the last MZEI Shareholders meeting was held on 26th August 2009. During the week of that meeting the MZEI share price traded in the .09 to.10 range. In the intervening 7 year period the funding of product development and commercialization of Asepticsure has absorbed in the region of 200m shares . In 2016 the Company has not communicated its intentions, nor specified why, it is necessary to authorize an increase of 105m new shares . In the interest of providing accountability and transparency to all shareholders this request for more authorised shares should be restricted to 55m shares, making a total of 450m authorised shares. lffurther authorization is required to fund company activities a shareholders meeting can be scheduled for on, or around, 15th December 2017.

https://www.sec.gov/divisions/corpfin/cf-noaction/14a-8/2016/alexmeldrum091916-14a8-incoming.pdf

----------

THE FANTASY WORLD THAT EDWIN G. MARSHALL LIVES IN...


Medizone International Announces Hospital Sterilization Initiative

10/01/2008 @ 8:35AM

PR Newswire (US)

"Mr. Edwin Marshall, Chairman and CEO of Medizone International stated, "With Dr. Shannon's leadership in this exciting new initiative, we anticipate being fully commercialized within 18 months."

-----

TO DATE, NOT ONE (1) SALE TO A HOSPITAL NOR ONE (1) HOSPITAL SERVICE CONTRACT HAS BEEN REPORTED, WORLDWIDE (The manufacture of the first production machine was announced back in April 2012)

----------

January 28, 2011

Joan Harrigan-Farrelly
Director
Antimicrobial Division
Office of Pesticide Programs
U.S Environment Protection Agency

Dear Ms. Harrigan-Farrelly:

On behalf of the Association for Professionals in Infection Prevention (APIC), the Society for Healthcare Epidemiology of America (SHEA) and the Association for the Healthcare Environment (AHE) formerly ASHES, we welcome the opportunity to comment on the topic of fogging applications for disinfectants. The issues are very pertinent to our organizations and we are responding collectively to reinforce our close agreement on mutual concerns, especially worker safety.....When used properly, HP also likely offers a greater margin of safety compared to other chemicals that can also be applied by vapor such as chlorine dioxide or ozone.(Davies A, 2011, in press JHI)

7. Are there any active ingredients that may be problematic for your facility as foggers?

Ingredients that affect OSHA exposure limits that may affect workers, especially agents such as formaldehyde or phenol-based agents, would be a concern. The latter were chemicals that stimulated investigation and ultimately specific recommendations against their use by CDC. Other chemicals such as chlorine dioxide and ozone also have many documented safety issues that would preclude their use in healthcare facilities.(Davies,JHI2011)